Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors
暂无分享,去创建一个
T. Rungrotmongkol | Y. Shigeta | K. Choowongkomon | Panupong Mahalapbutr | C. Kuhakarn | Thitinan Aiebchun | Jatuporn Meesin | O. Khaikate | Atima Auepattanapong | K. Hengphasatporn
[1] R. Harada,et al. Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO , 2022, Scientific Reports.
[2] H. Min,et al. Molecular targeted therapy for anticancer treatment , 2022, Experimental & Molecular Medicine.
[3] T. Rungrotmongkol,et al. Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling , 2022, ACS omega.
[4] T. Rungrotmongkol,et al. Halogenated Baicalein as a Promising Antiviral Agent toward SARS-CoV-2 Main Protease , 2022, J. Chem. Inf. Model..
[5] M. Tiseo,et al. A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine. , 2021, European journal of medicinal chemistry.
[6] Thanapon Charoenwongpaiboon,et al. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists , 2021, Journal of Molecular Liquids.
[7] Aiping Lu,et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties , 2021, Nucleic Acids Res..
[8] J. Chu,et al. Dibromopinocembrin and Dibromopinostrobin Are Potential Anti-Dengue Leads with Mild Animal Toxicity , 2020, Molecules.
[9] A. Lauria,et al. Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways , 2020, Molecules.
[10] Michael W. Schmidt,et al. Recent developments in the general atomic and molecular electronic structure system. , 2020, The Journal of chemical physics.
[11] S. Yokoyama,et al. Protein ligand interaction analysis against new CaMKK2 inhibitors by use of X-ray crystallography and the fragment molecular orbital (FMO) method. , 2020, Journal of molecular graphics & modelling.
[12] T. Rungrotmongkol,et al. Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases , 2020, ACS omega.
[13] T. Langer,et al. Multiple Virtual Screening Strategies for the Discovery of Novel Compounds Active Against Dengue Virus: A Hit Identification Study , 2019 .
[14] K. Choowongkomon,et al. Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli , 2019, Applied Microbiology and Biotechnology.
[15] Cheng-Ta Yang,et al. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) , 2019, International journal of molecular sciences.
[16] Junmei Wang,et al. End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. , 2019, Chemical reviews.
[17] T. Rungrotmongkol,et al. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. , 2019, Journal of molecular graphics & modelling.
[18] T. Rungrotmongkol,et al. Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors , 2019, Molecules.
[19] Riham F. George,et al. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors. , 2019, Bioorganic chemistry.
[20] B. F,et al. The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy. , 2018, Balkan journal of medical genetics : BJMG.
[21] N. Zhu,et al. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression , 2018, Journal of experimental & clinical cancer research : CR.
[22] Y. Zhen,et al. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis , 2018, Acta Pharmacologica Sinica.
[23] Pawaret Leowanawat,et al. TBAI/TBHP-Mediated Cascade Cyclization toward Sulfonylated Indeno[1,2-c]quinolines. , 2017, Organic letters.
[24] F. Totzke,et al. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance , 2017, Journal of enzyme inhibition and medicinal chemistry.
[25] Raj Kumar,et al. Dual inhibitors of epidermal growth factor receptor and topoisomerase IIα derived from a quinoline scaffold , 2016 .
[26] Ambily Nath Indu Viswanath,et al. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking. , 2015, Bioorganic & medicinal chemistry letters.
[27] S. Tsai,et al. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. , 2015, Biochimica et biophysica acta.
[28] Ya-Juan Qin,et al. Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors , 2013, PloS one.
[29] Fazlul H. Sarkar,et al. Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives , 2012, Front. Pharmacol..
[30] Ravi Radhakrishnan,et al. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain , 2012, The Biochemical journal.
[31] Caicun Zhou,et al. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians , 2012, Therapeutic Advances in Medical Oncology.
[32] E. Smit,et al. Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] F. Cappuzzo,et al. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer , 2009, Oncogene.
[34] Joseph M. Wu,et al. Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer , 2009, Journal of oncology.
[35] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[36] F. Ciardiello,et al. Erlotinib in cancer treatment. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] C. Carlin,et al. A Structural Model for the Membrane-bound Form of the Juxtamembrane Domain of the Epidermal Growth Factor Receptor* , 2005, Journal of Biological Chemistry.
[38] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[39] N. Hynes,et al. ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.
[40] Charles L. Brooks,et al. Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..
[41] G. Giaccone,et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[43] R. Roskoski. The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.
[44] H. Varmus,et al. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma , 2010, Disease Models & Mechanisms.